Palomar Medical Technologies, Inc. is pleased to announce that the Lux1540™ Fractional non-ablative laser handpiece has received the first clearance by the United States Food and Drug Administration (FDA) for the treatment of striae (stretch marks) using a fractional laser. This new clearance will allow aesthetic practitioners to treat the millions of women worldwide who have unwanted stretch marks.
Ongoing clinical studies have shown that subjects treated with the Lux1540 achieved an average improvement of between 51% and 75% in the appearance of their striae, based upon a blinded review of photographs comparing the pre-treatment appearance of striae versus the results three months post-treatment.
Francesca de Angelis, MD, a leading plastic surgeon from Naples, Italy who has led the research effort, noted, "Through our ongoing clinical study, and with thousands of satisfied patients treated throughout Italy, we have found that the Lux1540 is the first laser treatment for stretch marks that truly works."
"Our experience with the Palomar Lux1540 is consistent with the results seen in Europe," noted Vic Narurkar, MD, a dermatologist in San Francisco, CA and past president of the American Society of Cosmetic Dermatology and Aesthetic Surgery. "For the right patient, the Lux1540 provides a laser treatment option for stretch marks that offers significant improvement. The non-ablative fractional laser allows for comfortable treatments with little to no impact on the patient's daily activities."
Carolyn Chang, MD, Vice-Chair of Plastic Surgery at California Medical Center in San Francisco, believes fractional laser treatment for stretch marks will be a highly-requested procedure in her practice. "After pregnancy, women are always looking to eliminate their stretch marks. The Palomar laser can play a key role in the 'mommy makeover' so many new mothers are asking for."